Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U1111-1118-4027 | Registry Identifier | WHO |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study was to evaluate the long-term safety and efficacy of SYR-322, once daily (QD), to an α-glucosidase inhibitor, three times daily (TID), administered for 40 consecutive weeks in participants who completed a phase 2 dose-ranging study.
Both insulin hyposecretion and insulin-resistance are considered to be involved in the development of type 2 diabetes mellitus.
Takeda is developing SYR-322 (alogliptin) for the improvement of glycemic control in patients with type 2 diabetes mellitus. Alogliptin is an inhibitor of the dipeptidyl peptidase IV (DPP-IV) enzyme. DPP-IV is thought to be primarily responsible for the degradation of 2 peptide hormones released in response to nutrient ingestion. It is expected that inhibition of DPP-IV will improve glycemic control in patients with type 2 diabetes.
To evaluate the long-term safety and efficacy of alogliptin, this extension study was administered for 40 consecutive weeks (52 weeks from the start of treatment in the phase 2 dose-ranging study) to participants who had completed the phase 2 dose-ranging study SYR-322/CCT-001 (NCT01263470).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Alogliptin 6.25 mg QD | Experimental |
| |
| Alogliptin 12.5 mg QD | Experimental |
| |
| Alogliptin 25 mg QD | Experimental |
| |
| Alogliptin 50 mg QD | Experimental |
| |
| Voglibose 0.2-mg TID | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Alogliptin | Drug | Alogliptin 6.25 mg, tablets, orally, once daily for up to 40 weeks. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Adverse Events. | A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug and within 30 days after receiving the last dose of study drug. A TEAE may also be a pre-treatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug, which increases in intensity after the start of dosing. Adverse events data with onset occurring more than 30 days after last dose of study drug (AE start date - last dose date >30) will be listed, but not included in the summary tables below. | 52 Weeks. |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin (Week 12). | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 and glycosylated hemoglobin collected at baseline. | Baseline and Week 12. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Professor, Department of Medicine | Kawasaki Medical School | Study Director |
Not provided
Participants with a historical diagnosis of type 2 diabetes mellitus with uncontrolled blood glucose despite diet and exercise therapies were enrolled in one of 5, once-daily (QD) or three-times daily (TID) treatment groups.
Analyses were performed by treatment dose group or by treatment dose in this study.
Participants enrolled at 53 investigative sites in Japan from 10 May 2007 to 27 September 2008.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Alogliptin 6.25 mg Dose Group* → Alogliptin 6.25 mg Dose Group | Alogliptin 6.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks. *for participants from the 6.5 mg dosing ARM of the SYR-322/CCT-001 (NCT01263470) dose-ranging study. |
| FG001 | Alogliptin 12.5 mg Dose Group* → Alogliptin 12.5 mg Dose Group | Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks. *for participants from the 12.5 mg dosing ARM of the SYR-322/CCT-001 (NCT01263470) dose-ranging study. |
| FG002 | Alogliptin 25 mg Dose Group* → Alogliptin 25 mg Dose Group | Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks. *for participants from the 25 mg dosing ARM of the SYR-322/CCT-001 (NCT01263470) dose-ranging study. |
| FG003 | Alogliptin 50 mg Dose Group* → Alogliptin 50 mg Dose Group | Alogliptin 50 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks. *for participants from the 50 mg dosing ARM of the SYR-322/CCT-001 (NCT01263470) dose-ranging study. |
| FG004 | Voglibose 0.2 mg Dose Group* → Voglibose 0.2 mg Dose Group | Voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks. *for participants from the voglibose 0.2 mg dosing ARM of the SYR-322/CCT-001 (NCT01263470) dose-ranging study. |
| FG005 | Placebo Dose Group* → Alogliptin 6.25 mg Dose Group | Placebo-matching tablets, orally, once or three times daily for up to 40 weeks. *for participants from the placebo dosing ARM of the SYR-322/CCT-001 (NCT01263470) dose-ranging study. |
| FG006 | Placebo Dose Group* → Alogliptin 12.5 mg Dose Group | Placebo-matching tablets, orally, once or three times daily for up to 40 weeks. *for participants from the placebo dosing ARM of the SYR-322/CCT-001 (NCT01263470) dose-ranging study. |
| FG007 | Placebo Dose Group* → Alogliptin 25 mg Dose Group | Placebo-matching tablets, orally, once or three times daily for up to 40 weeks. *for participants from the placebo dosing ARM of the SYR-322/CCT-001 (NCT01263470) dose-ranging study. |
| FG008 | Placebo Dose Group* → Alogliptin 50 mg Dose Group | Placebo-matching tablets, orally, once or three times daily for up to 40 weeks. *for participants from the placebo dosing ARM of the SYR-322/CCT-001 (NCT01263470) dose-ranging study. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Enrolled - Long-Term Extension Study |
|
| ||||||||||||||||||
| Entered - Long-Term Extension Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Alogliptin 6.25 mg QD | Alogliptin 6.25 mg, tablets, orally, once daily for up to 40 weeks. |
| BG001 | Alogliptin 12.5 mg QD | Alogliptin 12.5 mg, tablets, orally, once daily for up to 40 weeks. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Number |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants With Adverse Events. | A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug and within 30 days after receiving the last dose of study drug. A TEAE may also be a pre-treatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug, which increases in intensity after the start of dosing. Adverse events data with onset occurring more than 30 days after last dose of study drug (AE start date - last dose date >30) will be listed, but not included in the summary tables below. | Adverse Event Profile in the Safety Analysis Set | Posted | Number | participants | 52 Weeks. |
|
Treatment-emergent adverse events are adverse events that started after the first dose of study drug the last dose of study drug.
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Alogliptin 6.25 mg QD | Alogliptin 6.25 mg, tablets, orally, once daily for up to 40 weeks. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Pneumonia | Infections and infestations | MedDRA (11.0) | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Nasopharyngitis | Infections and infestations | MedDRA (11.0) | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| General Manager | Japan Development Center, Pharmaceutical Development Division | +81-6-6204-5257 | clinicaltrialregistry@tpna.com |
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| D003920 | Diabetes Mellitus |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C520853 | alogliptin |
| C102817 | voglibose |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Alogliptin | Drug | Alogliptin 12.5 mg, tablets, orally, once daily for up to 40 weeks. |
|
|
| Alogliptin | Drug | Alogliptin 25 mg, tablets, orally, once daily for up to 40 weeks. |
|
|
| Alogliptin | Drug | Alogliptin 50 mg, tablets, orally, once daily for up to 40 weeks. |
|
|
| Voglibose | Drug | Voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks. |
|
|
| Change From Baseline in Glycosylated Hemoglobin (Week 16). |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 16 and glycosylated hemoglobin collected at baseline. |
| Baseline and Week 16. |
| Change From Baseline in Glycosylated Hemoglobin (Week 20). | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 20 and glycosylated hemoglobin collected at baseline. | Baseline and Week 20. |
| Change From Baseline in Glycosylated Hemoglobin (Week 24). | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 and glycosylated hemoglobin collected at baseline. | Baseline and Week 24. |
| Change From Baseline in Glycosylated Hemoglobin (Week 28). | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 28 and glycosylated hemoglobin collected at baseline. | Baseline and Week 28. |
| Change From Baseline in Glycosylated Hemoglobin (Week 32). | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 32 and glycosylated hemoglobin collected at baseline. | Baseline and Week 32. |
| Change From Baseline in Glycosylated Hemoglobin (Week 36). | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 36 and glycosylated hemoglobin collected at baseline. | Baseline and Week 36. |
| Change From Baseline in Glycosylated Hemoglobin (Week 40). | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 40 and glycosylated hemoglobin collected at baseline. | Baseline and Week 40. |
| Change From Baseline in Glycosylated Hemoglobin (Week 44). | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 44 and glycosylated hemoglobin collected at baseline. | Baseline and Week 44. |
| Change From Baseline in Glycosylated Hemoglobin (Week 48). | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 48 and glycosylated hemoglobin collected at baseline. | Baseline and Week 48. |
| Change From Baseline in Glycosylated Hemoglobin (Week 52). | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 52 and glycosylated hemoglobin collected at baseline. | Baseline and Week 52. |
| Change From Baseline in Glycosylated Hemoglobin (Final Visit). | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 52 or final visit and glycosylated hemoglobin collected at baseline. | Baseline and Final Visit (up to Week 52). |
| Change From Baseline in Fasting Plasma Glucose (Week 12). | The change between the value of fasting plasma glucose collected at week 12 and fasting plasma glucose collected at baseline. | Baseline and Week 12 |
| Change From Baseline in Fasting Plasma Glucose (Week 16). | The change between the value of fasting plasma glucose collected at week 16 and fasting plasma glucose collected at baseline. | Baseline and Week 16. |
| Change From Baseline in Fasting Plasma Glucose (Week 20). | The change between the value of fasting plasma glucose collected at week 20 and fasting plasma glucose collected at baseline. | Baseline and Week 20. |
| Change From Baseline in Fasting Plasma Glucose (Week 24). | The change between the value of fasting plasma glucose collected at week 24 and fasting plasma glucose collected at baseline. | Baseline and Week 24. |
| Change From Baseline in Fasting Plasma Glucose (Week 28). | The change between the value of fasting plasma glucose collected at week 28 and fasting plasma glucose collected at baseline. | Baseline and Week 28. |
| Change From Baseline in Fasting Plasma Glucose (Week 32). | The change between the value of fasting plasma glucose collected at week 32 and fasting plasma glucose collected at baseline. | Baseline and Week 32. |
| Change From Baseline in Fasting Plasma Glucose (Week 36). | The change between the value of fasting plasma glucose collected at week 36 and fasting plasma glucose collected at baseline. | Baseline and Week 36. |
| Change From Baseline in Fasting Plasma Glucose (Week 40). | The change between the value of fasting plasma glucose collected at week 40 and fasting plasma glucose collected at baseline. | Baseline and Week 40. |
| Change From Baseline in Fasting Plasma Glucose (Week 44). | The change between the value of fasting plasma glucose collected at week 44 and fasting plasma glucose collected at baseline. | Baseline and Week 44. |
| Change From Baseline in Fasting Plasma Glucose (Week 48). | The change between the value of fasting plasma glucose collected at week 48 and fasting plasma glucose collected at baseline. | Baseline and Week 48. |
| Change From Baseline in Fasting Plasma Glucose (Week 52). | The change between the value of fasting plasma glucose collected at week 52 and fasting plasma glucose collected at baseline. | Baseline and Week 52. |
| Change From Baseline in Fasting Plasma Glucose (Final Visit). | The change between the value of fasting plasma glucose collected at week 52 or final visit and fasting plasma glucose collected at baseline. | Baseline and Final Visit (up to Week 52). |
| Change From Baseline in Fasting C-peptide (Week 12). | The change between the value of fasting C-peptide collected at week 12 and fasting C-peptide collected at baseline. | Baseline and Week 12. |
| Change From Baseline in Fasting C-peptide (Week 16). | The change between the value of fasting C-peptide collected at week 16 and fasting C-peptide collected at baseline. | Baseline and Week 16. |
| Change From Baseline in Fasting C-peptide (Week 20). | The change between the value of fasting C-peptide collected at week 20 and fasting C-peptide collected at baseline. | Baseline and Week 20. |
| Change From Baseline in Fasting C-peptide (Week 24). | The change between the value of fasting C-peptide collected at week 24 and fasting C-peptide collected at baseline. | Baseline and Week 24. |
| Change From Baseline in Fasting C-peptide (Week 28). | The change between the value of fasting C-peptide collected at week 28 and fasting C-peptide collected at baseline. | Baseline and Week 28. |
| Change From Baseline in Fasting C-peptide (Week 32). | The change between the value of fasting C-peptide collected at week 32 and fasting C-peptide collected at baseline. | Baseline and Week 32. |
| Change From Baseline in Fasting C-peptide (Week 36). | The change between the value of fasting C-peptide collected at week 36 and fasting C-peptide collected at baseline. | Baseline and Week 36. |
| Change From Baseline in Fasting C-peptide (Week 40). | The change between the value of fasting C-peptide collected at week 40 and fasting C-peptide collected at baseline. | Baseline and Week 40. |
| Change From Baseline in Fasting C-peptide (Week 44). | The change between the value of fasting C-peptide collected at week 44 and fasting C-peptide collected at baseline. | Baseline and Week 44. |
| Change From Baseline in Fasting C-peptide (Week 48). | The change between the value of fasting C-peptide collected at week 48 and fasting C-peptide collected at baseline. | Baseline and Week 48. |
| Change From Baseline in Fasting C-peptide (Week 52). | The change between the value of fasting C-peptide collected at week 52 and fasting C-peptide collected at baseline. | Baseline and Week 52. |
| Change From Baseline in Fasting C-peptide (Final Visit). | The change between the value of fasting C-peptide collected at week 52 or final visit and fasting C-peptide collected at baseline. | Baseline and Final Visit (up to Week 52). |
| Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (2-hr Postprandial Value) (Week 12). | The change between the value of blood glucose collected at week 12 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Baseline and Week 12. |
| Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (2-hr Postprandial Value) (Week 24). | The change between the value of blood glucose collected at week 24 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Baseline and Week 24. |
| Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (2-hr Postprandial Value) (Week 52). | The change between the value of blood glucose collected at week 52 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Baseline and Week 52. |
| Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (2-hr Postprandial Value) (Final Visit). | The change between the value of blood glucose collected at week 52 or final visit and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Baseline and Final Visit (up to Week 52). |
| Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (AUC (0-2)) (Week 12). | The change between the value of blood glucose collected at week 12 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Baseline and Week 12. |
| Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (AUC (0-2)) (Week 24). | The change between the value of blood glucose collected at week 24 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Baseline and Week 24. |
| Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (AUC (0-2)) (Week 52). | The change between the value of blood glucose collected at week 52 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Baseline and Week 52. |
| Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (AUC (0-2)) (Final Visit). | The change between the value of blood glucose collected at week 52 or final visit and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Baseline and Final Visit (up to Week 52). |
| Change From Baseline in C-peptide Measured by Meal Tolerance Testing (AUC(0-2)) (Week 12). | The change between the value of C-peptide collected at week 12 and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Baseline and Week 12. |
| Change From Baseline in C-peptide Measured by Meal Tolerance Testing (AUC(0-2)) (Week 24). | The change between the value of C-peptide collected at week 24 and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Baseline and Week 24. |
| Change From Baseline in C-peptide Measured by Meal Tolerance Testing (AUC(0-2)) (Week 52). | The change between the value of C-peptide collected at week 52 and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Baseline and Week 52. |
| Change From Baseline in C-peptide Measured by Meal Tolerance Testing (AUC(0-2)) (Final Visit). | The change between the value of C-peptide collected at week 52 or final visit and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Baseline and Final Visit (up to Week 52). |
| Change From Baseline in Insulin Measured by Meal Tolerance Testing (AUC(0-2)) (Week 12). | The change between the value of insulin collected at week 12 and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Baseline and Week 12 |
| Change From Baseline in Insulin Measured by Meal Tolerance Testing (AUC(0-2)) (Week 24). | The change between the value of insulin collected at week 24 and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Baseline and Week 24. |
| Change From Baseline in Insulin Measured by Meal Tolerance Testing (AUC(0-2)) (Week 52). | The change between the value of insulin collected at week 52 and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Baseline and Week 52. |
| Change From Baseline in Insulin Measured by Meal Tolerance Testing (AUC(0-2)) (Final Visit). | The change between the value of insulin collected at week 52 or final visit and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Baseline and Final Visit (up to Week 52). |
| Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)) (Week 12). | The change between the value of glucagons collected at week 12 and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Baseline and Week 12 |
| Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)) (Week 24). | The change between the value of glucagons collected at week 24 and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Baseline and Week 24. |
| Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)) (Week 52). | The change between the value of glucagons collected at week 52 and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Baseline and Week 52. |
| Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)) (Final Visit). | The change between the value of glucagons collected at week 52 or final visit and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Baseline and Final Visit (up to Week 52). |
| Adverse Event |
|
| COMPLETED |
|
| NOT COMPLETED |
|
|
| BG002 | Alogliptin 25 mg QD | Alogliptin 25 mg, tablets, orally, once daily for up to 40 weeks. |
| BG003 | Alogliptin 50 mg QD | Alogliptin 50 mg, tablets, orally, once daily for up to 40 weeks. |
| BG004 | Voglibose 0.2 mg TID | Voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks. |
| BG005 | Total | Total of all reporting groups |
| participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| OG001 |
| Alogliptin 12.5 mg QD |
Alogliptin 12.5 mg, tablets, orally, once daily for up to 40 weeks. |
| OG002 | Alogliptin 25 mg QD | Alogliptin 25 mg, tablets, orally, once daily for up to 40 weeks. |
| OG003 | Alogliptin 50 mg QD | Alogliptin 50 mg, tablets, orally, once daily for up to 40 weeks. |
| OG004 | Voglibose 0.2 mg TID | Voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks. |
|
|
| Secondary | Change From Baseline in Glycosylated Hemoglobin (Week 12). | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 and glycosylated hemoglobin collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | percentage of Glycosylated Hemoglobin | Baseline and Week 12. |
|
|
|
|
| Secondary | Change From Baseline in Glycosylated Hemoglobin (Week 16). | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 16 and glycosylated hemoglobin collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | percentage of Glycosylated Hemoglobin | Baseline and Week 16. |
|
|
|
|
| Secondary | Change From Baseline in Glycosylated Hemoglobin (Week 20). | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 20 and glycosylated hemoglobin collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | percentage of Glycosylated Hemoglobin | Baseline and Week 20. |
|
|
|
|
| Secondary | Change From Baseline in Glycosylated Hemoglobin (Week 24). | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 and glycosylated hemoglobin collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | percentage of Glycosylated Hemoglobin | Baseline and Week 24. |
|
|
|
|
| Secondary | Change From Baseline in Glycosylated Hemoglobin (Week 28). | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 28 and glycosylated hemoglobin collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | percentage of Glycosylated Hemoglobin | Baseline and Week 28. |
|
|
|
|
| Secondary | Change From Baseline in Glycosylated Hemoglobin (Week 32). | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 32 and glycosylated hemoglobin collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | percentage of Glycosylated Hemoglobin | Baseline and Week 32. |
|
|
|
|
| Secondary | Change From Baseline in Glycosylated Hemoglobin (Week 36). | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 36 and glycosylated hemoglobin collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | percentage of Glycosylated Hemoglobin | Baseline and Week 36. |
|
|
|
|
| Secondary | Change From Baseline in Glycosylated Hemoglobin (Week 40). | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 40 and glycosylated hemoglobin collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | percentage of Glycosylated Hemoglobin | Baseline and Week 40. |
|
|
|
|
| Secondary | Change From Baseline in Glycosylated Hemoglobin (Week 44). | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 44 and glycosylated hemoglobin collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | percentage of Glycosylated Hemoglobin | Baseline and Week 44. |
|
|
|
|
| Secondary | Change From Baseline in Glycosylated Hemoglobin (Week 48). | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 48 and glycosylated hemoglobin collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | percentage of Glycosylated Hemoglobin | Baseline and Week 48. |
|
|
|
|
| Secondary | Change From Baseline in Glycosylated Hemoglobin (Week 52). | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 52 and glycosylated hemoglobin collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | percentage of Glycosylated Hemoglobin | Baseline and Week 52. |
|
|
|
|
| Secondary | Change From Baseline in Glycosylated Hemoglobin (Final Visit). | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 52 or final visit and glycosylated hemoglobin collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | percentage of Glycosylated Hemoglobin | Baseline and Final Visit (up to Week 52). |
|
|
|
|
| Secondary | Change From Baseline in Fasting Plasma Glucose (Week 12). | The change between the value of fasting plasma glucose collected at week 12 and fasting plasma glucose collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | mg/dL | Baseline and Week 12 |
|
|
|
|
| Secondary | Change From Baseline in Fasting Plasma Glucose (Week 16). | The change between the value of fasting plasma glucose collected at week 16 and fasting plasma glucose collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | mg/dL | Baseline and Week 16. |
|
|
|
|
| Secondary | Change From Baseline in Fasting Plasma Glucose (Week 20). | The change between the value of fasting plasma glucose collected at week 20 and fasting plasma glucose collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | mg/dL | Baseline and Week 20. |
|
|
|
|
| Secondary | Change From Baseline in Fasting Plasma Glucose (Week 24). | The change between the value of fasting plasma glucose collected at week 24 and fasting plasma glucose collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | mg/dL | Baseline and Week 24. |
|
|
|
|
| Secondary | Change From Baseline in Fasting Plasma Glucose (Week 28). | The change between the value of fasting plasma glucose collected at week 28 and fasting plasma glucose collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | mg/dL | Baseline and Week 28. |
|
|
|
|
| Secondary | Change From Baseline in Fasting Plasma Glucose (Week 32). | The change between the value of fasting plasma glucose collected at week 32 and fasting plasma glucose collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | mg/dL | Baseline and Week 32. |
|
|
|
|
| Secondary | Change From Baseline in Fasting Plasma Glucose (Week 36). | The change between the value of fasting plasma glucose collected at week 36 and fasting plasma glucose collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | mg/dL | Baseline and Week 36. |
|
|
|
|
| Secondary | Change From Baseline in Fasting Plasma Glucose (Week 40). | The change between the value of fasting plasma glucose collected at week 40 and fasting plasma glucose collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | mg/dL | Baseline and Week 40. |
|
|
|
|
| Secondary | Change From Baseline in Fasting Plasma Glucose (Week 44). | The change between the value of fasting plasma glucose collected at week 44 and fasting plasma glucose collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | mg/dL | Baseline and Week 44. |
|
|
|
|
| Secondary | Change From Baseline in Fasting Plasma Glucose (Week 48). | The change between the value of fasting plasma glucose collected at week 48 and fasting plasma glucose collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | mg/dL | Baseline and Week 48. |
|
|
|
|
| Secondary | Change From Baseline in Fasting Plasma Glucose (Week 52). | The change between the value of fasting plasma glucose collected at week 52 and fasting plasma glucose collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | mg/dL | Baseline and Week 52. |
|
|
|
|
| Secondary | Change From Baseline in Fasting Plasma Glucose (Final Visit). | The change between the value of fasting plasma glucose collected at week 52 or final visit and fasting plasma glucose collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | mg/dL | Baseline and Final Visit (up to Week 52). |
|
|
|
|
| Secondary | Change From Baseline in Fasting C-peptide (Week 12). | The change between the value of fasting C-peptide collected at week 12 and fasting C-peptide collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | ng/mL | Baseline and Week 12. |
|
|
|
|
| Secondary | Change From Baseline in Fasting C-peptide (Week 16). | The change between the value of fasting C-peptide collected at week 16 and fasting C-peptide collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | ng/mL | Baseline and Week 16. |
|
|
|
|
| Secondary | Change From Baseline in Fasting C-peptide (Week 20). | The change between the value of fasting C-peptide collected at week 20 and fasting C-peptide collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | ng/mL | Baseline and Week 20. |
|
|
|
|
| Secondary | Change From Baseline in Fasting C-peptide (Week 24). | The change between the value of fasting C-peptide collected at week 24 and fasting C-peptide collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | ng/mL | Baseline and Week 24. |
|
|
|
|
| Secondary | Change From Baseline in Fasting C-peptide (Week 28). | The change between the value of fasting C-peptide collected at week 28 and fasting C-peptide collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | ng/mL | Baseline and Week 28. |
|
|
|
|
| Secondary | Change From Baseline in Fasting C-peptide (Week 32). | The change between the value of fasting C-peptide collected at week 32 and fasting C-peptide collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | ng/mL | Baseline and Week 32. |
|
|
|
|
| Secondary | Change From Baseline in Fasting C-peptide (Week 36). | The change between the value of fasting C-peptide collected at week 36 and fasting C-peptide collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | ng/mL | Baseline and Week 36. |
|
|
|
|
| Secondary | Change From Baseline in Fasting C-peptide (Week 40). | The change between the value of fasting C-peptide collected at week 40 and fasting C-peptide collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | ng/mL | Baseline and Week 40. |
|
|
|
|
| Secondary | Change From Baseline in Fasting C-peptide (Week 44). | The change between the value of fasting C-peptide collected at week 44 and fasting C-peptide collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | ng/mL | Baseline and Week 44. |
|
|
|
|
| Secondary | Change From Baseline in Fasting C-peptide (Week 48). | The change between the value of fasting C-peptide collected at week 48 and fasting C-peptide collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | ng/mL | Baseline and Week 48. |
|
|
|
|
| Secondary | Change From Baseline in Fasting C-peptide (Week 52). | The change between the value of fasting C-peptide collected at week 52 and fasting C-peptide collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | ng/mL | Baseline and Week 52. |
|
|
|
|
| Secondary | Change From Baseline in Fasting C-peptide (Final Visit). | The change between the value of fasting C-peptide collected at week 52 or final visit and fasting C-peptide collected at baseline. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | ng/mL | Baseline and Final Visit (up to Week 52). |
|
|
|
|
| Secondary | Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (2-hr Postprandial Value) (Week 12). | The change between the value of blood glucose collected at week 12 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | mg/dL | Baseline and Week 12. |
|
|
|
|
| Secondary | Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (2-hr Postprandial Value) (Week 24). | The change between the value of blood glucose collected at week 24 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | mg/dL | Baseline and Week 24. |
|
|
|
|
| Secondary | Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (2-hr Postprandial Value) (Week 52). | The change between the value of blood glucose collected at week 52 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | mg/dL | Baseline and Week 52. |
|
|
|
|
| Secondary | Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (2-hr Postprandial Value) (Final Visit). | The change between the value of blood glucose collected at week 52 or final visit and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | mg/dL | Baseline and Final Visit (up to Week 52). |
|
|
|
|
| Secondary | Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (AUC (0-2)) (Week 12). | The change between the value of blood glucose collected at week 12 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | mg·hr/dL | Baseline and Week 12. |
|
|
|
|
| Secondary | Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (AUC (0-2)) (Week 24). | The change between the value of blood glucose collected at week 24 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | mg·hr/dL | Baseline and Week 24. |
|
|
|
|
| Secondary | Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (AUC (0-2)) (Week 52). | The change between the value of blood glucose collected at week 52 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | mg·hr/dL | Baseline and Week 52. |
|
|
|
|
| Secondary | Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (AUC (0-2)) (Final Visit). | The change between the value of blood glucose collected at week 52 or final visit and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | mg·hr/dL | Baseline and Final Visit (up to Week 52). |
|
|
|
|
| Secondary | Change From Baseline in C-peptide Measured by Meal Tolerance Testing (AUC(0-2)) (Week 12). | The change between the value of C-peptide collected at week 12 and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | ng·hr/mL | Baseline and Week 12. |
|
|
|
|
| Secondary | Change From Baseline in C-peptide Measured by Meal Tolerance Testing (AUC(0-2)) (Week 24). | The change between the value of C-peptide collected at week 24 and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | ng·hr/mL | Baseline and Week 24. |
|
|
|
|
| Secondary | Change From Baseline in C-peptide Measured by Meal Tolerance Testing (AUC(0-2)) (Week 52). | The change between the value of C-peptide collected at week 52 and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | ng·hr/mL | Baseline and Week 52. |
|
|
|
|
| Secondary | Change From Baseline in C-peptide Measured by Meal Tolerance Testing (AUC(0-2)) (Final Visit). | The change between the value of C-peptide collected at week 52 or final visit and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | ng·hr/mL | Baseline and Final Visit (up to Week 52). |
|
|
|
|
| Secondary | Change From Baseline in Insulin Measured by Meal Tolerance Testing (AUC(0-2)) (Week 12). | The change between the value of insulin collected at week 12 and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | μU·hr/mL | Baseline and Week 12 |
|
|
|
|
| Secondary | Change From Baseline in Insulin Measured by Meal Tolerance Testing (AUC(0-2)) (Week 24). | The change between the value of insulin collected at week 24 and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | μU·hr/mL | Baseline and Week 24. |
|
|
|
|
| Secondary | Change From Baseline in Insulin Measured by Meal Tolerance Testing (AUC(0-2)) (Week 52). | The change between the value of insulin collected at week 52 and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | μU·hr/mL | Baseline and Week 52. |
|
|
|
|
| Secondary | Change From Baseline in Insulin Measured by Meal Tolerance Testing (AUC(0-2)) (Final Visit). | The change between the value of insulin collected at week 52 or final visit and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | μU·hr/mL | Baseline and Final Visit (up to Week 52). |
|
|
|
|
| Secondary | Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)) (Week 12). | The change between the value of glucagons collected at week 12 and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | pg·hr/mL | Baseline and Week 12 |
|
|
|
|
| Secondary | Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)) (Week 24). | The change between the value of glucagons collected at week 24 and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | pg·hr/mL | Baseline and Week 24. |
|
|
|
|
| Secondary | Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)) (Week 52). | The change between the value of glucagons collected at week 52 and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | pg·hr/mL | Baseline and Week 52. |
|
|
|
|
| Secondary | Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)) (Final Visit). | The change between the value of glucagons collected at week 52 or final visit and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. | Values are Summary Statistics. | Posted | Mean | Standard Deviation | pg·hr/mL | Baseline and Final Visit (up to Week 52). |
|
|
|
|
| 2 |
| 96 |
| 78 |
| 96 |
| EG001 | Alogliptin 12.5 mg QD | Alogliptin 12.5 mg, tablets, orally, once daily for up to 40 weeks. | 8 | 101 | 81 | 101 |
| EG002 | Alogliptin 25 mg QD | Alogliptin 25 mg, tablets, orally, once daily for up to 40 weeks. | 8 | 97 | 81 | 97 |
| EG003 | Alogliptin 50 mg QD | Alogliptin 50 mg, tablets, orally, once daily for up to 40 weeks. | 5 | 97 | 88 | 97 |
| EG004 | Voglibose 0.2 mg TID | Voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks. | 4 | 83 | 74 | 83 |
| Cellulitis | Infections and infestations | MedDRA (11.0) | Systematic Assessment |
|
| Gastroenteritis | Infections and infestations | MedDRA (11.0) | Systematic Assessment |
|
| Bladder cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.0) | Systematic Assessment |
|
| Colon cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.0) | Systematic Assessment |
|
| Gastric cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.0) | Systematic Assessment |
|
| Meningioma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.0) | Systematic Assessment |
|
| Pancreatic carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.0) | Systematic Assessment |
|
| Papillary thyroid cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.0) | Systematic Assessment |
|
| Hepatic cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.0) | Systematic Assessment |
|
| Breast cancer female | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.0) | Systematic Assessment |
|
| Large intestine carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.0) | Systematic Assessment |
|
| Drug hypersensitivity | Immune system disorders | MedDRA (11.0) | Systematic Assessment |
|
| Hypoglycaemia | Metabolism and nutrition disorders | MedDRA (11.0) | Systematic Assessment |
|
| Cerebral infarction | Nervous system disorders | MedDRA (11.0) | Systematic Assessment |
|
| Atrial fibrillation | Cardiac disorders | MedDRA (11.0) | Systematic Assessment |
|
| Myocardial infarction | Cardiac disorders | MedDRA (11.0) | Systematic Assessment |
|
| Hypertension | Vascular disorders | MedDRA (11.0) | Systematic Assessment |
|
| Crohn's disease | Gastrointestinal disorders | MedDRA (11.0) | Systematic Assessment |
|
| Gastric ulcer haemorrhage | Gastrointestinal disorders | MedDRA (11.0) | Systematic Assessment |
|
| Inguinal hernia | Gastrointestinal disorders | MedDRA (11.0) | Systematic Assessment |
|
| Pancreatitis acute | Gastrointestinal disorders | MedDRA (11.0) | Systematic Assessment |
|
| Cholelithiasis | Hepatobiliary disorders | MedDRA (11.0) | Systematic Assessment |
|
| Accident | Injury, poisoning and procedural complications | MedDRA (11.0) | Systematic Assessment |
|
| Bronchitis | Infections and infestations | MedDRA (11.0) | Systematic Assessment |
|
| Gastroenteritis | Infections and infestations | MedDRA (11.0) | Systematic Assessment |
|
| Pharyngitis | Infections and infestations | MedDRA (11.0) | Systematic Assessment |
|
| Tinea pedis | Infections and infestations | MedDRA (11.0) | Systematic Assessment |
|
| Cystitis | Infections and infestations | MedDRA (11.0) | Systematic Assessment |
|
| Rhinitis | Infections and infestations | MedDRA (11.0) | Systematic Assessment |
|
| Seasonal allergy | Immune system disorders | MedDRA (11.0) | Systematic Assessment |
|
| Hyperlipidaemia | Metabolism and nutrition disorders | MedDRA (11.0) | Systematic Assessment |
|
| Hypoglycaemia | Metabolism and nutrition disorders | MedDRA (11.0) | Systematic Assessment |
|
| Headache | Nervous system disorders | MedDRA (11.0) | Systematic Assessment |
|
| Dizziness | Nervous system disorders | MedDRA (11.0) | Systematic Assessment |
|
| Hypoaesthesia | Nervous system disorders | MedDRA (11.0) | Systematic Assessment |
|
| Cerebral infarction | Nervous system disorders | MedDRA (11.0) | Systematic Assessment |
|
| Cataract | Eye disorders | MedDRA (11.0) | Systematic Assessment |
|
| Diabetic retinopathy | Eye disorders | MedDRA (11.0) | Systematic Assessment |
|
| Conjunctivitis allergic | Eye disorders | MedDRA (11.0) | Systematic Assessment |
|
| Tinnitus | Ear and labyrinth disorders | MedDRA (11.0) | Systematic Assessment |
|
| Hypertension | Vascular disorders | MedDRA (11.0) | Systematic Assessment |
|
| Upper respiratory tract inflammation | Respiratory, thoracic and mediastinal disorders | MedDRA (11.0) | Systematic Assessment |
|
| Rhinitis allergic | Respiratory, thoracic and mediastinal disorders | MedDRA (11.0) | Systematic Assessment |
|
| Pharyngolaryngeal pain | Respiratory, thoracic and mediastinal disorders | MedDRA (11.0) | Systematic Assessment |
|
| Constipation | Gastrointestinal disorders | MedDRA (11.0) | Systematic Assessment |
|
| Dental caries | Gastrointestinal disorders | MedDRA (11.0) | Systematic Assessment |
|
| Flatulence | Gastrointestinal disorders | MedDRA (11.0) | Systematic Assessment |
|
| Abdominal distension | Gastrointestinal disorders | MedDRA (11.0) | Systematic Assessment |
|
| Abdominal pain upper | Gastrointestinal disorders | MedDRA (11.0) | Systematic Assessment |
|
| Gastritis | Gastrointestinal disorders | MedDRA (11.0) | Systematic Assessment |
|
| Diarrhoea | Gastrointestinal disorders | MedDRA (11.0) | Systematic Assessment |
|
| Periodontal disease | Gastrointestinal disorders | MedDRA (11.0) | Systematic Assessment |
|
| Gallbladder polyp | Hepatobiliary disorders | MedDRA (11.0) | Systematic Assessment |
|
| Eczema | Skin and subcutaneous tissue disorders | MedDRA (11.0) | Systematic Assessment |
|
| Dermatitis contact | Skin and subcutaneous tissue disorders | MedDRA (11.0) | Systematic Assessment |
|
| Rash | Skin and subcutaneous tissue disorders | MedDRA (11.0) | Systematic Assessment |
|
| Urticaria | Skin and subcutaneous tissue disorders | MedDRA (11.0) | Systematic Assessment |
|
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA (11.0) | Systematic Assessment |
|
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA (11.0) | Systematic Assessment |
|
| Musculoskeletal pain | Musculoskeletal and connective tissue disorders | MedDRA (11.0) | Systematic Assessment |
|
| Osteoarthritis | Musculoskeletal and connective tissue disorders | MedDRA (11.0) | Systematic Assessment |
|
| Spinal osteoarthritis | Musculoskeletal and connective tissue disorders | MedDRA (11.0) | Systematic Assessment |
|
| Musculoskeletal stiffness | Musculoskeletal and connective tissue disorders | MedDRA (11.0) | Systematic Assessment |
|
| Pain in extremity | Musculoskeletal and connective tissue disorders | MedDRA (11.0) | Systematic Assessment |
|
| Periarthritis | Musculoskeletal and connective tissue disorders | MedDRA (11.0) | Systematic Assessment |
|
| Intervertebral disc protrusion | Musculoskeletal and connective tissue disorders | MedDRA (11.0) | Systematic Assessment |
|
| Arthritis | Musculoskeletal and connective tissue disorders | MedDRA (11.0) | Systematic Assessment |
|
| Malaise | General disorders | MedDRA (11.0) | Systematic Assessment |
|
| Blood creatine phosphokinase increased | Investigations | MedDRA (11.0) | Systematic Assessment |
|
| Alanine aminotransferase increased | Investigations | MedDRA (11.0) | Systematic Assessment |
|
| Gamma-glutamyltransferase increased | Investigations | MedDRA (11.0) | Systematic Assessment |
|
| Aspartate aminotransferase increased | Investigations | MedDRA (11.0) | Systematic Assessment |
|
| Fall | Injury, poisoning and procedural complications | MedDRA (11.0) | Systematic Assessment |
|
| Arthropod sting | Injury, poisoning and procedural complications | MedDRA (11.0) | Systematic Assessment |
|
The clinical trial contract states that information should never be disclosed without prior consent of the sponsor, although it does not specify the number of days during which disclosure of information is limited.
| Mean Difference (Final Values) |
| -0.548 |
| 2-Sided |
| 95 |
| -0.739 |
| -0.358 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -0.590 | 2-Sided | 95 | -0.779 | -0.401 | No | Superiority or Other |
| Mean Difference (Final Values) | -0.708 | 2-Sided | 95 | -0.894 | -0.522 | No | Superiority or Other |
| Mean Difference (Final Values) |
| -0.493 |
| 2-Sided |
| 95 |
| -0.684 |
| -0.302 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -0.510 | 2-Sided | 95 | -0.706 | -0.314 | No | Superiority or Other |
| Mean Difference (Final Values) | -0.647 | 2-Sided | 95 | -0.834 | -0.461 | No | Superiority or Other |
| Mean Difference (Final Values) |
| -0.395 |
| 2-Sided |
| 95 |
| -0.598 |
| -0.192 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -0.405 | 2-Sided | 95 | -0.616 | -0.195 | No | Superiority or Other |
| Mean Difference (Final Values) | -0.583 | 2-Sided | 95 | -0.780 | -0.386 | No | Superiority or Other |
| Mean Difference (Final Values) |
| -0.319 |
| 2-Sided |
| 95 |
| -0.550 |
| -0.088 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -0.370 | 2-Sided | 95 | -0.601 | -0.139 | No | Superiority or Other |
| Mean Difference (Final Values) | -0.533 | 2-Sided | 95 | -0.752 | -0.314 | No | Superiority or Other |
| Mean Difference (Final Values) |
| -0.241 |
| 2-Sided |
| 95 |
| -0.471 |
| -0.011 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -0.357 | 2-Sided | 95 | -0.590 | -0.124 | No | Superiority or Other |
| Mean Difference (Final Values) | -0.467 | 2-Sided | 95 | -0.692 | -0.242 | No | Superiority or Other |
| Mean Difference (Final Values) |
| -0.294 |
| 2-Sided |
| 95 |
| -0.542 |
| -0.046 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -0.341 | 2-Sided | 95 | -0.579 | -0.103 | No | Superiority or Other |
| Mean Difference (Final Values) | -0.487 | 2-Sided | 95 | -0.722 | -0.252 | No | Superiority or Other |
| Mean Difference (Final Values) |
| -0.234 |
| 2-Sided |
| 95 |
| -0.491 |
| 0.023 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -0.375 | 2-Sided | 95 | -0.605 | -0.145 | No | Superiority or Other |
| Mean Difference (Final Values) | -0.488 | 2-Sided | 95 | -0.724 | -0.252 | No | Superiority or Other |
| Mean Difference (Final Values) |
| -0.193 |
| 2-Sided |
| 95 |
| -0.453 |
| 0.067 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -0.374 | 2-Sided | 95 | -0.596 | -0.152 | No | Superiority or Other |
| Mean Difference (Final Values) | -0.490 | 2-Sided | 95 | -0.723 | -0.256 | No | Superiority or Other |
| Mean Difference (Final Values) |
| -0.236 |
| 2-Sided |
| 95 |
| -0.477 |
| 0.005 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -0.360 | 2-Sided | 95 | -0.608 | -0.113 | No | Superiority or Other |
| Mean Difference (Final Values) | -0.435 | 2-Sided | 95 | -0.679 | -0.191 | No | Superiority or Other |
| Mean Difference (Final Values) |
| -0.262 |
| 2-Sided |
| 95 |
| -0.516 |
| -0.008 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -0.358 | 2-Sided | 95 | -0.614 | -0.103 | No | Superiority or Other |
| Mean Difference (Final Values) | -0.432 | 2-Sided | 95 | -0.690 | -0.174 | No | Superiority or Other |
| Mean Difference (Final Values) |
| -0.277 |
| 2-Sided |
| 95 |
| -0.539 |
| -0.015 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -0.373 | 2-Sided | 95 | -0.637 | -0.109 | No | Superiority or Other |
| Mean Difference (Final Values) | -0.477 | 2-Sided | 95 | -0.741 | -0.213 | No | Superiority or Other |
| Mean Difference (Final Values) |
| -0.245 |
| 2-Sided |
| 95 |
| -0.492 |
| 0.003 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -0.408 | 2-Sided | 95 | -0.654 | -0.161 | No | Superiority or Other |
| Mean Difference (Final Values) | -0.638 | 2-Sided | 95 | -0.874 | -0.402 | No | Superiority or Other |
| Mean Difference (Final Values) |
| -11.70 |
| 2-Sided |
| 95 |
| -19.23 |
| -4.18 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -13.41 | 2-Sided | 95 | -20.68 | -6.15 | No | Superiority or Other |
| Mean Difference (Final Values) | -19.38 | 2-Sided | 95 | -26.93 | -11.83 | No | Superiority or Other |
| Mean Difference (Final Values) |
| -9.39 |
| 2-Sided |
| 95 |
| -17.48 |
| -1.30 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -10.56 | 2-Sided | 95 | -18.58 | -2.54 | No | Superiority or Other |
| Mean Difference (Final Values) | -12.37 | 2-Sided | 95 | -21.44 | -3.31 | No | Superiority or Other |
| Mean Difference (Final Values) |
| -10.73 |
| 2-Sided |
| 95 |
| -18.97 |
| -2.49 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -9.21 | 2-Sided | 95 | -17.20 | -1.23 | No | Superiority or Other |
| Mean Difference (Final Values) | -15.49 | 2-Sided | 95 | -24.27 | -6.72 | No | Superiority or Other |
| Mean Difference (Final Values) |
| -3.36 |
| 2-Sided |
| 95 |
| -12.16 |
| 5.44 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -5.43 | 2-Sided | 95 | -13.30 | 2.44 | No | Superiority or Other |
| Mean Difference (Final Values) | -11.90 | 2-Sided | 95 | -20.74 | -3.06 | No | Superiority or Other |
| Mean Difference (Final Values) |
| -6.25 |
| 2-Sided |
| 95 |
| -15.84 |
| 3.35 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -6.93 | 2-Sided | 95 | -15.28 | 1.41 | No | Superiority or Other |
| Mean Difference (Final Values) | -12.73 | 2-Sided | 95 | -22.67 | -2.78 | No | Superiority or Other |
| Mean Difference (Final Values) |
| -3.77 |
| 2-Sided |
| 95 |
| -13.53 |
| 5.99 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -5.85 | 2-Sided | 95 | -14.36 | 2.67 | No | Superiority or Other |
| Mean Difference (Final Values) | -11.22 | 2-Sided | 95 | -20.72 | -1.73 | No | Superiority or Other |
| Mean Difference (Final Values) |
| -5.90 |
| 2-Sided |
| 95 |
| -15.64 |
| 3.84 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -8.47 | 2-Sided | 95 | -16.52 | -0.42 | No | Superiority or Other |
| Mean Difference (Final Values) | -12.47 | 2-Sided | 95 | -22.18 | -2.76 | No | Superiority or Other |
| Mean Difference (Final Values) |
| -0.98 |
| 2-Sided |
| 95 |
| -10.16 |
| 8.21 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -1.88 | 2-Sided | 95 | -9.71 | 5.95 | No | Superiority or Other |
| Mean Difference (Final Values) | -9.38 | 2-Sided | 95 | -18.59 | -0.18 | No | Superiority or Other |
| Mean Difference (Final Values) |
| -3.70 |
| 2-Sided |
| 95 |
| -13.10 |
| 5.70 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -3.97 | 2-Sided | 95 | -12.94 | 5.00 | No | Superiority or Other |
| Mean Difference (Final Values) | -9.74 | 2-Sided | 95 | -19.40 | -0.08 | No | Superiority or Other |
| Mean Difference (Final Values) |
| -7.29 |
| 2-Sided |
| 95 |
| -16.53 |
| 1.94 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -9.30 | 2-Sided | 95 | -17.93 | -0.67 | No | Superiority or Other |
| Mean Difference (Final Values) | -11.88 | 2-Sided | 95 | -21.83 | -1.93 | No | Superiority or Other |
| Mean Difference (Final Values) |
| -7.05 |
| 2-Sided |
| 95 |
| -16.34 |
| 2.24 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -8.86 | 2-Sided | 95 | -17.47 | -0.26 | No | Superiority or Other |
| Mean Difference (Final Values) | -13.51 | 2-Sided | 95 | -23.12 | -3.89 | No | Superiority or Other |
| Mean Difference (Final Values) |
| -6.70 |
| 2-Sided |
| 95 |
| -15.66 |
| 2.25 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -8.28 | 2-Sided | 95 | -16.64 | 0.07 | No | Superiority or Other |
| Mean Difference (Final Values) | -18.82 | 2-Sided | 95 | -27.39 | -10.24 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 0.226 |
| 2-Sided |
| 95 |
| 0.002 |
| 0.451 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | 0.230 | 2-Sided | 95 | 0.008 | 0.453 | No | Superiority or Other |
| Mean Difference (Final Values) | 0.282 | 2-Sided | 95 | 0.041 | 0.524 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 0.228 |
| 2-Sided |
| 95 |
| -0.010 |
| 0.467 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | 0.339 | 2-Sided | 95 | 0.095 | 0.584 | No | Superiority or Other |
| Mean Difference (Final Values) | 0.468 | 2-Sided | 95 | 0.184 | 0.752 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 0.511 |
| 2-Sided |
| 95 |
| 0.236 |
| 0.786 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | 0.437 | 2-Sided | 95 | 0.190 | 0.685 | No | Superiority or Other |
| Mean Difference (Final Values) | 0.718 | 2-Sided | 95 | 0.413 | 1.022 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 0.358 |
| 2-Sided |
| 95 |
| 0.104 |
| 0.612 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | 0.308 | 2-Sided | 95 | 0.076 | 0.540 | No | Superiority or Other |
| Mean Difference (Final Values) | 0.331 | 2-Sided | 95 | 0.098 | 0.565 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 0.245 |
| 2-Sided |
| 95 |
| -0.026 |
| 0.516 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | 0.294 | 2-Sided | 95 | 0.035 | 0.552 | No | Superiority or Other |
| Mean Difference (Final Values) | 0.329 | 2-Sided | 95 | 0.032 | 0.626 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 0.420 |
| 2-Sided |
| 95 |
| 0.138 |
| 0.703 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | 0.460 | 2-Sided | 95 | 0.178 | 0.742 | No | Superiority or Other |
| Mean Difference (Final Values) | 0.384 | 2-Sided | 95 | 0.085 | 0.683 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 0.249 |
| 2-Sided |
| 95 |
| -0.043 |
| 0.542 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | 0.111 | 2-Sided | 95 | -0.196 | 0.417 | No | Superiority or Other |
| Mean Difference (Final Values) | 0.333 | 2-Sided | 95 | 0.010 | 0.656 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 0.349 |
| 2-Sided |
| 95 |
| -0.156 |
| 0.855 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | 0.140 | 2-Sided | 95 | -0.297 | 0.577 | No | Superiority or Other |
| Mean Difference (Final Values) | 0.308 | 2-Sided | 95 | -0.075 | 0.690 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 0.579 |
| 2-Sided |
| 95 |
| -0.035 |
| 1.194 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | 0.647 | 2-Sided | 95 | 0.054 | 1.241 | No | Superiority or Other |
| Mean Difference (Final Values) | 0.252 | 2-Sided | 95 | -0.280 | 0.785 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 0.643 |
| 2-Sided |
| 95 |
| -0.305 |
| 1.591 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | 0.144 | 2-Sided | 95 | -0.599 | 0.888 | No | Superiority or Other |
| Mean Difference (Final Values) | 0.250 | 2-Sided | 95 | -0.673 | 1.173 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 0.033 |
| 2-Sided |
| 95 |
| -2.712 |
| 2.779 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -0.600 | 2-Sided | 95 | -3.273 | 2.073 | No | Superiority or Other |
| Mean Difference (Final Values) | -0.400 | 2-Sided | 95 | -2.874 | 2.074 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 0.260 |
| 2-Sided |
| 95 |
| -0.001 |
| 0.520 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | 0.136 | 2-Sided | 95 | -0.126 | 0.398 | No | Superiority or Other |
| Mean Difference (Final Values) | 0.298 | 2-Sided | 95 | 0.042 | 0.553 | No | Superiority or Other |
| Mean Difference (Final Values) |
| -3.02 |
| 2-Sided |
| 95 |
| -12.45 |
| 6.40 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -8.41 | 2-Sided | 95 | -18.77 | 1.96 | No | Superiority or Other |
| Mean Difference (Final Values) | -8.96 | 2-Sided | 95 | -18.35 | 0.44 | No | Superiority or Other |
| Mean Difference (Final Values) |
| -1.08 |
| 2-Sided |
| 95 |
| -11.41 |
| 9.24 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -1.08 | 2-Sided | 95 | -12.91 | 10.75 | No | Superiority or Other |
| Mean Difference (Final Values) | -0.66 | 2-Sided | 95 | -11.32 | 9.99 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 1.63 |
| 2-Sided |
| 95 |
| -8.63 |
| 11.89 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -2.69 | 2-Sided | 95 | -13.36 | 7.98 | No | Superiority or Other |
| Mean Difference (Final Values) | -9.20 | 2-Sided | 95 | -20.58 | 2.17 | No | Superiority or Other |
| Mean Difference (Final Values) |
| -2.04 |
| 2-Sided |
| 95 |
| -11.74 |
| 7.66 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -5.44 | 2-Sided | 95 | -15.62 | 4.75 | No | Superiority or Other |
| Mean Difference (Final Values) | -13.28 | 2-Sided | 95 | -23.83 | -2.74 | No | Superiority or Other |
| Mean Difference (Final Values) |
| -5.45 |
| 2-Sided |
| 95 |
| -23.93 |
| 13.02 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -17.80 | 2-Sided | 95 | -35.46 | -0.13 | No | Superiority or Other |
| Mean Difference (Final Values) | -30.58 | 2-Sided | 95 | -47.75 | -13.41 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 9.86 |
| 2-Sided |
| 95 |
| -13.56 |
| 33.28 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -7.44 | 2-Sided | 95 | -30.25 | 15.37 | No | Superiority or Other |
| Mean Difference (Final Values) | -12.80 | 2-Sided | 95 | -34.75 | 9.15 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 3.35 |
| 2-Sided |
| 95 |
| -18.20 |
| 24.90 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -3.64 | 2-Sided | 95 | -26.03 | 18.74 | No | Superiority or Other |
| Mean Difference (Final Values) | -23.37 | 2-Sided | 95 | -47.08 | 0.34 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 1.37 |
| 2-Sided |
| 95 |
| -21.21 |
| 23.94 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -11.20 | 2-Sided | 95 | -32.69 | 10.30 | No | Superiority or Other |
| Mean Difference (Final Values) | -34.90 | 2-Sided | 95 | -56.85 | -12.96 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 1.358 |
| 2-Sided |
| 95 |
| 0.752 |
| 1.965 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | 1.350 | 2-Sided | 95 | 0.724 | 1.975 | No | Superiority or Other |
| Mean Difference (Final Values) | 1.380 | 2-Sided | 95 | 0.804 | 1.955 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 1.448 |
| 2-Sided |
| 95 |
| 0.780 |
| 2.115 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | 1.243 | 2-Sided | 95 | 0.616 | 1.870 | No | Superiority or Other |
| Mean Difference (Final Values) | 1.481 | 2-Sided | 95 | 0.827 | 2.136 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 1.585 |
| 2-Sided |
| 95 |
| -3.476 |
| 6.647 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | 0.517 | 2-Sided | 95 | -8.151 | 9.184 | No | Superiority or Other |
| Mean Difference (Final Values) | 1.277 | 2-Sided | 95 | -2.191 | 4.744 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 1.304 |
| 2-Sided |
| 95 |
| 0.679 |
| 1.930 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | 0.992 | 2-Sided | 95 | 0.400 | 1.585 | No | Superiority or Other |
| Mean Difference (Final Values) | 1.263 | 2-Sided | 95 | 0.674 | 1.853 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 18.026 |
| 2-Sided |
| 95 |
| 12.466 |
| 23.585 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | 19.838 | 2-Sided | 95 | 14.379 | 25.297 | No | Superiority or Other |
| Mean Difference (Final Values) | 15.368 | 2-Sided | 95 | 8.677 | 22.060 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 20.714 |
| 2-Sided |
| 95 |
| 14.563 |
| 26.864 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | 19.063 | 2-Sided | 95 | 13.125 | 25.002 | No | Superiority or Other |
| Mean Difference (Final Values) | 15.233 | 2-Sided | 95 | 6.618 | 23.847 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 13.950 |
| 2-Sided |
| 95 |
| 7.767 |
| 20.133 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | 15.221 | 2-Sided | 95 | 9.191 | 21.251 | No | Superiority or Other |
| Mean Difference (Final Values) | 13.366 | 2-Sided | 95 | 5.847 | 20.885 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 12.978 |
| 2-Sided |
| 95 |
| 7.556 |
| 18.399 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | 15.076 | 2-Sided | 95 | 9.808 | 20.345 | No | Superiority or Other |
| Mean Difference (Final Values) | 13.087 | 2-Sided | 95 | 6.561 | 19.614 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 11.85 |
| 2-Sided |
| 95 |
| -1.49 |
| 25.19 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | 9.72 | 2-Sided | 95 | -5.12 | 24.56 | No | Superiority or Other |
| Mean Difference (Final Values) | 0.82 | 2-Sided | 95 | -13.26 | 14.90 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 10.57 |
| 2-Sided |
| 95 |
| -7.21 |
| 28.35 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | 8.45 | 2-Sided | 95 | -10.08 | 26.98 | No | Superiority or Other |
| Mean Difference (Final Values) | 6.82 | 2-Sided | 95 | -10.67 | 24.30 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 2.48 |
| 2-Sided |
| 95 |
| -15.61 |
| 20.57 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | -0.66 | 2-Sided | 95 | -21.00 | 19.68 | No | Superiority or Other |
| Mean Difference (Final Values) | 1.29 | 2-Sided | 95 | -17.47 | 20.05 | No | Superiority or Other |
| Mean Difference (Final Values) |
| 4.94 |
| 2-Sided |
| 95 |
| -11.14 |
| 21.03 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) | 3.65 | 2-Sided | 95 | -14.42 | 21.73 | No | Superiority or Other |
| Mean Difference (Final Values) | -0.68 | 2-Sided | 95 | -17.24 | 15.89 | No | Superiority or Other |